^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    oxaliplatin

    i
    Other names: 1 OHP, 1670 RB, L OHP, NSC 266046, PR 54780, RP 54780, SR 96669, 1670 RB7
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, DNA cross linking agent
    Related drugs:
    18h
    Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) (clinicaltrials.gov)
    P2, N=128, Not yet recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial • pMMR
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Hetronifly (serplulimab)
    21h
    PARERE: PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (clinicaltrials.gov)
    P2, N=214, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Trial completion date: Dec 2025 --> Mar 2026
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Idylla™ NRAS-BRAF Mutation Test
    |
    Avastin (bevacizumab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan
    1d
    A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov)
    P1, N=542, Recruiting, Hoffmann-La Roche | Trial completion date: Nov 2028 --> Aug 2030 | Trial primary completion date: Aug 2027 --> Aug 2030
    Trial completion date • Trial primary completion date
    |
    FoundationOne® Liquid CDx
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • divarasib (RG6330) • Itovebi (inavolisib) • SY-5609 • tiragolumab (RG6058)
    1d
    Multiple-pathway cGAS-STING activation with enhanced mild photothermal therapy through glycolysis regulation for boosting gastric cancer immunotherapy. (PubMed, Mater Today Bio)
    To address these issues, we developed a mild PTT (mPTT) nanoparticle based on mesoporous polydopamine (MPDA), loaded with oxaliplatin (OXP) and manganese dioxide (MnO2), and coated with tumor cell membranes to enhance the targeting capability...The activation of both adaptive and innate immune responses triggers a potent antitumor immune reaction, which, combined with chemotherapy and enhanced mPTT, significantly suppresses tumor growth, metastasis and recurrence. This strategy not only enhances the targeting of chemotherapeutic drugs but also provides new possibilities for expanding the field of immunotherapy in gastric cancer by regulating tumor metabolism and enhancing mPTT.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    oxaliplatin
    2d
    Cistanche tubulosa phenylethanol glycoside liposome ameliorates oxaliplatin-induced peripheral neuropathy by promoting RNA N6-methyladenosine modification. (PubMed, Phytomedicine)
    CPhG alleviates oxaliplatin-induced peripheral neuropathy by dual mechanisms: reducing neuroinflammation via IL-6 suppression and promoting neuronal survival and regeneration through AKT activation and m6A-dependent epitranscriptomic regulation. Compared with duloxetine, CPhG demonstrated superior neuroprotective and anti-inflammatory effects, supporting its potential as a novel therapeutic agent for OIPN.
    Journal
    |
    IL6 (Interleukin 6) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3)
    |
    oxaliplatin
    2d
    ANCHOR: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=748, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Avastin (bevacizumab) • Focus V (anlotinib) • capecitabine • oxaliplatin
    2d
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=150 --> 90
    Enrollment change
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • TQB2825
    3d
    A Study on the Network Pharmacology of HQGZWWT that Prevents CINP by Inhibiting Ferroptosis through Regulation of the P38/c-FOS/NF-kB Pathway. (PubMed, J Ethnopharmacol)
    HQGZWWT significantly ameliorated CINP by increasing sciatic nerve conduction velocity, reducing oxidative stress and inflammatory responses, and inhibiting ferroptosis. Both HQGZWWT and its active monomeric component paeoniflorin protect neurons by suppressing ferroptosis, thereby exerting preventive and therapeutic effects against CINP. These findings provide new insights into the clinical treatment of CINP with HQGZWWT. Inhibiting ferroptosis by regulating the p38/c-FOS/NF-κB pathway through HQGZWWT and its primary monomeric component paeoniflorin represents a promising therapeutic strategy for preventing and treating oxaliplatin-induced CINP.
    Journal
    |
    FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
    |
    oxaliplatin
    3d
    The role and mechanism of gut microbiota in oxaliplatin-induced peripheral neuropathy (ChiCTR2600117203)
    P=N/A, N=30, Not yet recruiting, Tongde Hospital of Zhejiang Province; Tongde Hospital of Zhejiang Province
    New trial
    |
    oxaliplatin
    3d
    Clinical Efficacy of Pucotenlimab Combined with Lenvatinib and SOX Versus SOX Alone in Patients with HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Center Randomized Controlled Trial (ChiCTR2600116583)
    P=N/A, N=100, Not yet recruiting, Department of Gastric Surgery, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lenvima (lenvatinib) • oxaliplatin • Puyouheng (pucotenlimab)
    3d
    A Phase II Clinical Trial of PD-L1 Expression-Based Epaploitovorilimab Combined with Chemotherapy as First-Line Treatment for Metastatic Gastric Cancer: Single-Arm, Open-Label (ChiCTR2500115675)
    P=N/A, N=30, Recruiting, The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    oxaliplatin
    3d
    Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study (ChiCTR2500114600)
    P=N/A, N=150, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital
    New trial
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • oxaliplatin • irinotecan • leucovorin calcium